Close Menu

NEW YORK (GenomeWeb) – Veracyte said today that 10 new Blue Cross Blue Shield plans recently issued positive coverage decisions for its Afirma Gene Expression Classifier for use in thyroid cancer diagnosis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.